Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with an ECOG performance score of 0 to 2 (a measure of how much a person's cancer affects their daily activities — confirm with trial site)
- People who are 18 years of age or older
- People who have multiple myeloma that has also developed into tumours outside the bone marrow (called extramedullary plasmacytoma)
Who may not be able to join:
- People who have previously received any treatment that targets a protein called BCMA
- People whose multiple myeloma has spread to the brain or spinal cord, or who show signs of it affecting the membranes surrounding the brain or spinal cord
- People with a known allergy, sensitivity, or intolerance to the study drug (teclistamab) or any of its ingredients
- People who have been diagnosed with plasma cell leukaemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary amyloid light-chain amyloidosis (these are specific blood or bone marrow conditions — confirm with trial site if unsure which category applies)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8613502181109
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
ORR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.